利多卡因治疗支气管哮喘患者的临床应用

Clinical application of Lidocaine in treatment of bronchial asthma patients

目的:观察利多卡因(LC)治疗重度支气管哮喘(哮喘)患者74例的临床效果。方法:回顾性分析哮喘患者147例,并根据过敏源分为花草过敏哮喘(PHAA)和COPD诱发哮喘(COPDAA)。其中花草过敏哮喘患者16例,随机分为哮喘急性发作治疗组和对照组,每组各4例以及哮喘持续状态治疗组和对照组,每组各4例;COPD诱发哮喘患者131例,随机分为哮喘急性发作治疗组(32例)和对照组(29例)以及哮喘持续状态治疗组(34例)和对照组(36例)。以上各治疗组患者给予LC治疗为主;各对照组患者则以给予氨茶碱(Ami)治疗为主。PHAA患者不配用消炎药物;COPDAA患者在综合治疗方案:即在应用地塞米松(DE)、青霉素(BEN)和吸氧(Oi)等治疗的基础上,治疗组患者加用LC;对照组患者加用Ami。LC和Ami药物的疗效判定有效时间限于用药后60 min内哮喘终止。结果:LC治疗PHAA患者8例,总有效率为100%;LC治疗COPDAA急性发作患者32例和哮喘持续状态患者34例,总有效率分别是71.87%和70.58%。治疗组患者的总有效率显著高于对照组。结论:LC是治疗重度哮喘患者最理想的首先药物。

Objective: To observe clinical therapeutic effects of Lidocaine in treating 74 cases with serious bronchial asthma.Methods: 147 cases with serious bronchial asthma were collected and divided randomly into 8 groups,and retrospectively analyzed,Among them,there were 4 groups of PHAA( the asthma attack resulted from pollen hypersensitivity) bronchial asthma( 16 cases) and there were 4 groups of COPDAA( the asthma attack resulted from COPD) Bronchial asthma( 131 cases). The asthmatic acute attack of PHAA bronchial asthma group was divided into therapeutic group and control group with 4 cases in each group,and the persistent PHAA bronchial asthma were group was divided into therapeutic group and control group with 4 cases in each group. 61 cases of asthmatic acute attack of COPDAA bronchial asthma were divided into group was divided into therapeutic group( 32) and control group( 29),and the persistent COPDAA bronchial asthma group was divided into therapeutic group( 34) and control group( 36). The above therapeutic groups were mainly treated with Lidocaine( LC),while the control groups were treated with Aminophylline( Ami).There were no antiphlogistic drugs in PHAA bronchial asthma. For the COPDAA bronchial asthma patients,on the basis of combined treatment( such as,Dexamethasone( De),Benzylpenicillin( Ben),oxygen inhalation( Oi) and so on),Lidocaine was added for the therapeutic group,and Aminophylline was added for the control group. The asthma stopping 60 minutes after the drug was used was a criterion for judging the efficacies of Lidocaine and Aminophylline. Results: The total effective rates of LC in the treatment of the PHAA patients,asthmatic acute attack of COPDAA bronchial asthma patients and persistent asthma patients were 100%,71. 87% and70. 58%,separately. The total effective rate of therapeutic group was significant higher than that of control group. Conclusions: LC is the Best initial selection in treating with severe bronchial asthma.